Headlands Technologies LLC Purchases New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Headlands Technologies LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,985 shares of the company’s stock, valued at approximately $132,000.

A number of other large investors have also recently made changes to their positions in TEVA. Stifel Financial Corp increased its position in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after acquiring an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $4,966,000. Asset Management One Co. Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after purchasing an additional 58,413 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $3,340,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 6.9 %

Shares of TEVA stock opened at $13.83 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $15.68 billion, a P/E ratio of -9.54, a PEG ratio of 1.44 and a beta of 0.82. The company has a 50 day moving average of $16.52 and a 200-day moving average of $18.01. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TEVA shares. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.